PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE.

HemaSphere

A. Lal, R. C. Brown, T. Coates, T. Kalfa, J. Kwiatkowski, J. Brevard, C. Trenor, K. Wood, S. Sheth. PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022 Jun 1; 6(Suppl):2102-2103.

2022

https://researcherprofiles.org/profile/425025843

A. Lal, R. C. Brown, T. Coates, T. Kalfa, J. Kwiatkowski, J. Brevard, C. Trenor, K. Wood, S. Sheth

Northern California Comprehensive Thalassemia Center

Search form

You are here

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE.